CN106232831B - 通过表达谱分析对淋巴瘤类型进行亚型分类的方法 - Google Patents

通过表达谱分析对淋巴瘤类型进行亚型分类的方法 Download PDF

Info

Publication number
CN106232831B
CN106232831B CN201480072382.7A CN201480072382A CN106232831B CN 106232831 B CN106232831 B CN 106232831B CN 201480072382 A CN201480072382 A CN 201480072382A CN 106232831 B CN106232831 B CN 106232831B
Authority
CN
China
Prior art keywords
gene expression
dlbcl
genbank accession
sample
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480072382.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106232831A (zh
Inventor
路易斯·M·施陶特
乔治·W·赖特
戴维·威廉·斯科特
约瑟夫·M·康纳斯
兰迪·D·加斯科因
莉萨·里姆萨
埃利亚斯·坎波圭里
雷蒙德·塔布斯
蒂莫西·C·格雷纳
詹姆斯·罗伯特·库克
傅凯
保罗·迈克尔·威廉姆斯
栗志坚
伊莱恩·S·贾菲
丽塔·M·布拉齐耶尔
安德烈亚斯·罗森瓦尔德
埃伦德·B·什梅兰德
荣·C·陈
格尔曼·奥特
扬·德拉比
丹尼斯·魏森贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Columbia Cancer Agency BCCA
Julius Maximilians Universitaet Wuerzburg
Universitat de Barcelona UB
Hospital Clinic de Barcelona
Oslo Universitetssykehus hf
Cleveland Clinic Foundation
Oregon Health and Science University
University of Nebraska System
Arizona's Public Universities
US Department of Health and Human Services
Original Assignee
British Columbia Cancer Agency BCCA
Julius Maximilians Universitaet Wuerzburg
Universitat de Barcelona UB
Hospital Clinic de Barcelona
Oslo Universitetssykehus hf
Cleveland Clinic Foundation
Oregon Health and Science University
University of Nebraska System
Arizona's Public Universities
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency BCCA, Julius Maximilians Universitaet Wuerzburg, Universitat de Barcelona UB, Hospital Clinic de Barcelona, Oslo Universitetssykehus hf, Cleveland Clinic Foundation, Oregon Health and Science University, University of Nebraska System, Arizona's Public Universities, US Department of Health and Human Services filed Critical British Columbia Cancer Agency BCCA
Publication of CN106232831A publication Critical patent/CN106232831A/zh
Application granted granted Critical
Publication of CN106232831B publication Critical patent/CN106232831B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480072382.7A 2013-11-06 2014-11-05 通过表达谱分析对淋巴瘤类型进行亚型分类的方法 Active CN106232831B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900553P 2013-11-06 2013-11-06
US61/900,553 2013-11-06
PCT/US2014/064161 WO2015069790A1 (en) 2013-11-06 2014-11-05 Method for subtyping lymphoma types by means expression profiling

Publications (2)

Publication Number Publication Date
CN106232831A CN106232831A (zh) 2016-12-14
CN106232831B true CN106232831B (zh) 2021-02-26

Family

ID=51987470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480072382.7A Active CN106232831B (zh) 2013-11-06 2014-11-05 通过表达谱分析对淋巴瘤类型进行亚型分类的方法

Country Status (9)

Country Link
US (2) US10607717B2 (enExample)
EP (2) EP3594359B1 (enExample)
JP (2) JP6657105B2 (enExample)
KR (1) KR102357699B1 (enExample)
CN (1) CN106232831B (enExample)
AU (1) AU2014346788B8 (enExample)
CA (1) CA2929826C (enExample)
ES (2) ES2923942T3 (enExample)
WO (1) WO2015069790A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
US10609336B2 (en) * 2015-04-16 2020-03-31 Offender Smartphone Monitoring, LLC Monitoring process
AU2016291708B2 (en) 2015-07-13 2020-12-24 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
BR112018006393A2 (pt) 2015-09-29 2018-10-09 Htg Molecular Diagnostics, Inc. método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit
EP3413885A4 (en) 2016-02-08 2019-09-18 Beyondspring Pharmaceuticals, Inc. COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
EP3445873B1 (en) * 2016-04-20 2020-11-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Evaluation of mantle cell lymphoma and methods related thereto
JP6871271B2 (ja) * 2016-05-13 2021-05-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｄｌｂｃｌを分類するための方法および組成物
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
US11696250B2 (en) * 2016-11-09 2023-07-04 Intel Corporation UE and devices for detach handling
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
EP3638814B8 (en) 2017-06-14 2023-06-21 The United States of America, as Represented by The Secretary, Department of Health and Human Services Method for determining lymphoma type
EP3665196B1 (en) * 2017-08-08 2022-10-19 F. Hoffmann-La Roche AG Obinutuzumab treatment of a dlbcl patient subgroup
EP3714271A1 (en) * 2017-11-20 2020-09-30 Julius-Maximilians-Universität Würzburg Cd19cart cells eliminate myeloma cells that express very low levels of cd19
AU2018374219C1 (en) 2017-12-01 2023-05-11 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
EP3718572B1 (en) 2017-12-01 2024-07-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
KR102834361B1 (ko) 2017-12-01 2025-07-17 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
EP3732185B1 (en) 2017-12-29 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
JP7515456B2 (ja) * 2018-08-01 2024-07-12 ジェネンテック， インコーポレイテッド Ｄｌｂｃｌの細胞起源のサブタイプの予測及びキャラクタリゼーション
EP3842534A4 (en) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID AND METHOD OF USE THEREOF
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3115804A1 (en) * 2018-10-15 2020-04-23 Provincial Health Services Authority Gene expression profiles for b-cell lymphoma and uses thereof
WO2020102244A1 (en) * 2018-11-14 2020-05-22 Beyondspring Pharmaceuticals, Inc. Methods of treating cancer using tubulin binding agents
KR20210110839A (ko) 2018-12-28 2021-09-09 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 핵산을 함유하는 조성물 및 접합체, 이의 제조 방법 및 용도
AU2020245086A1 (en) * 2019-03-28 2021-10-28 Centre Henri Becquerel Classification of B-Cell non-Hodgkin Lymphomas
CN111850114A (zh) * 2019-04-25 2020-10-30 上海交通大学医学院附属瑞金医院 一组用于评估弥漫大b细胞淋巴瘤分子分型的基因群，其试剂盒及分析方法
WO2020233651A1 (zh) * 2019-05-22 2020-11-26 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CA3139195A1 (en) 2019-05-22 2020-11-26 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
EP4004237A1 (en) * 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG Systems and methods for cell of origin determination from variant calling data
JP2022544393A (ja) 2019-08-12 2022-10-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド マクロファージ刺激１受容体（ｍｓｔ１ｒ）バリアント及びその使用
CN111621565B (zh) * 2020-05-07 2023-12-15 杭州可帮基因科技有限公司 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置
CN111785370B (zh) * 2020-07-01 2024-05-17 医渡云（北京）技术有限公司 病历数据处理方法及装置、计算机存储介质、电子设备
MX2022016244A (es) * 2020-07-08 2023-02-27 Dayton Therapeutics Ag Satraplatino para usarse en el tratamiento de neoplasmas linfoides.
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN113186289B (zh) * 2021-05-12 2023-02-24 清华大学深圳国际研究生院 lncRNA在肾癌尿液筛查和肾癌治疗中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
DK0834575T3 (da) 1990-12-06 2002-04-02 Affymetrix Inc A Delaware Corp Identifikation af nucleinsyrer i prøver
JP2001524926A (ja) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ オリゴマーの雑多ライブラリーの集合体を合成する方法
ATE262374T1 (de) 1991-11-22 2004-04-15 Affymetrix Inc Kombinatorische strategien für polymersynthese
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5550215A (en) 1991-11-22 1996-08-27 Holmes; Christopher P. Polymer reversal on solid surfaces
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
EP0758403B1 (en) 1994-05-05 1998-06-24 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
EP0902885A4 (en) 1996-05-16 2006-09-27 Affymetrix Inc SYSTEMS AND METHODS FOR DETECTION OF BRANDED PRODUCTS
ATE291097T1 (de) 1997-10-31 2005-04-15 Affymetrix Inc A Delaware Corp Expressionsprofile in adulten und fötalen organen
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
US6020198A (en) 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
US7105293B2 (en) 2000-09-19 2006-09-12 Whitehead Institute For Biomedical Research Genetic markers for tumors
US20030194701A1 (en) 2000-11-20 2003-10-16 Golub Todd R. Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
WO2003024956A1 (en) 2001-09-21 2003-03-27 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
JP5717937B2 (ja) 2002-12-06 2015-05-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害療法を用いた患者の同定、判定および治療方法
PL2287156T3 (pl) 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
US20110152115A1 (en) 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
ES2368741T3 (es) 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
WO2006034573A1 (en) 2004-09-27 2006-04-06 Med Biogene Inc. Hematological cancer profiling system
WO2006110264A2 (en) 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
EP2222875B1 (en) * 2007-11-07 2014-08-20 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
DK2245199T3 (da) 2008-02-01 2014-02-03 Gen Hospital Corp Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande
EP2294420B8 (en) 2008-06-06 2015-10-21 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Survival predictor for diffuse large B cell lymphoma
IN2012DN00866A (enExample) 2009-07-16 2015-07-10 Gen Hospital Corp
ES2352777B1 (es) 2009-07-31 2012-01-23 Hospital Clinic De Barcelona Metodo y kit para el pronostico del linfoma de celulas del manto
CA2778953C (en) * 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US20130058863A1 (en) 2010-02-04 2013-03-07 Jake Yue Chen 4-Protein Biomarker Panel for the Diagnosis of Lymphoma from Biospecimen
EP2569335B1 (en) * 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
WO2012016332A1 (en) 2010-08-04 2012-02-09 Med Biogene Inc. Prognostic gene signatures for non-small cell lung cancer
US9365640B2 (en) * 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CA2858383A1 (en) 2011-12-09 2013-06-13 British Columbia Cancer Agency Branch Predicting prognosis in classic hodgkin lymphoma
JP2015509489A (ja) * 2012-02-10 2015-03-30 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ がんの処置のためのグリシン開裂系の阻害
US9803245B2 (en) 2012-03-14 2017-10-31 University Health Network Signature for predicting clinical outcome in human HER2+ breast cancer
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
WO2014197936A1 (en) 2013-06-14 2014-12-18 The State Of Queensland Acting Through Its Department Of Health Biomarkers and use thereof in identification of b-cell lymphoproliferative disorders
AU2014360328B2 (en) 2013-12-06 2021-04-01 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
WO2016057705A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma;George Wright等;《PNAS》;20030819;第100卷(第17期);第9991–9996页 *
Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival;S. Blenk等;《Cancer Informatics》;20071231;第3卷;第399–420页 *

Also Published As

Publication number Publication date
ES2738289T3 (es) 2020-01-21
US10607717B2 (en) 2020-03-31
EP3594359B1 (en) 2022-05-18
EP3594359A1 (en) 2020-01-15
KR20160127713A (ko) 2016-11-04
EP3066215B1 (en) 2019-04-24
AU2014346788A1 (en) 2016-05-26
US20160283653A1 (en) 2016-09-29
JP6657105B2 (ja) 2020-03-04
US20200143906A1 (en) 2020-05-07
WO2015069790A9 (en) 2016-06-02
JP2017502686A (ja) 2017-01-26
EP3066215A1 (en) 2016-09-14
AU2014346788B8 (en) 2021-01-28
WO2015069790A1 (en) 2015-05-14
CA2929826C (en) 2022-08-16
CA2929826A1 (en) 2015-05-14
US11574704B2 (en) 2023-02-07
JP2020078323A (ja) 2020-05-28
AU2014346788A8 (en) 2016-06-16
ES2923942T3 (es) 2022-10-03
CN106232831A (zh) 2016-12-14
KR102357699B1 (ko) 2022-02-04
JP7016129B2 (ja) 2022-02-04
AU2014346788B2 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CN106232831B (zh) 通过表达谱分析对淋巴瘤类型进行亚型分类的方法
US10697975B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
US10196691B2 (en) Colon cancer gene expression signatures and methods of use
KR20070084488A (ko) 고형 종양의 예후 및 치료를 위한 방법 및 시스템
US20050287541A1 (en) Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
EP1683862B1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
US9469879B2 (en) Lymphoma prognostic methods and kits
WO2017184861A1 (en) Evaluation of mantle cell lymphoma and methods related thereto
AU2007277142B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
AU2004219989B2 (en) Expression profiling of tumours
Uchida Gene expression profiling for biomarker discovery
EP3638814A1 (en) Method for determining lymphoma type
HK1228459B (en) Method for subtyping lymphoma types by means of expression profiling
HK1228459A1 (en) Method for subtyping lymphoma types by means of expression profiling
NZ612471B2 (en) Colon cancer gene expression signatures and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant